Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Pembrolizumab biosimilar by Formycon for Non-Small Cell Lung Cancer: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer. According to...
Data Insights
Pembrolizumab biosimilar by Formycon for Melanoma: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase I for Melanoma. According to GlobalData, Phase I...